Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials

Wenxia Sun; Jing Li

doi:10.1080/07357907.2019.1634089

Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials

Cancer Invest. 2019;37(6):253-264. doi: 10.1080/07357907.2019.1634089. Epub 2019 Jul 15.

Authors

Wenxia Sun¹, Jing Li²

Affiliations

¹ a Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Sichuan Industrial Institute of Antibiotics, Chengdu University , Chengdu , China.
² b College of Pharmacy, Southwest Minzu University , Chengdu , People's Republic of China.

PMID: 31303065
DOI: 10.1080/07357907.2019.1634089

Abstract

We fully investigate the skin toxicities of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in cancer patients. The studies about randomized controlled trials in cancer treatment with EGFR-TKIs were retrieved and the systematic evaluation was conducted. The results suggest that EGFR-TKIs significantly increase the risk of skin toxicities including all-grade rash, pruritus, dry skin, and high-grade rash, pruritus. However, the risk of high-grade dry skin did not increase. Rash was the most common toxicity. Physicians should be aware of skin toxicities and should monitor cancer patients when receiving EGFR-TKIs.

Keywords: EGFR-TKIs; cancer; meta-analysis; skin toxicities; systematic review.

Publication types

Meta-Analysis
Systematic Review

MeSH terms

ErbB Receptors / antagonists & inhibitors*
Exanthema / chemically induced
Humans
Neoplasms / drug therapy*
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use*
Randomized Controlled Trials as Topic
Skin / drug effects*

Substances

Protein Kinase Inhibitors
ErbB Receptors